P3355
P3781
Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot StudyPomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple MyelomaMLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaIxazomib Maintenance Study in Patients With AL AmyloidosisIxazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationPharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or LymphomaEfficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to TreatmentA Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMyeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaIPD in RRMM Characterized With Genomic Abnormalities of Adverse PrognosticVRD as Induction Followed by IR Maintenance in Patients With Newly Diagnosed High Risk Multiple MyelomaIbrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom MacroglobulinemiaPembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple MyelomaIxazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL AmyloidosisA Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple MyelomaIxazomib in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to BortezomibStudy of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple MyelomaStudy of Oral IXAZOMIB in Adult Patients With Relapsed or Refractory Light Chain AmyloidosisStudy Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaA Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaA Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and DexamethasoneA Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyA Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell LymphomaIxazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaA Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple MyelomaA Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With MyelomaQuality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot StudyIntravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaLenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell TransplantSIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple SclerosisIxazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple MyelomaDaratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaMyeloma-Developing Regimens Using Genomics (MyDRUG)Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide: A Study in Relapsed or Refractory Multiple MyelomaPhase 2 Maintenance Trial: Ixazomib Compared to Ixazomib-Lenalidomide Combination as Maintenance Therapy for Frontline Multiple Myeloma Patients
P4844
KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsAn evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibPharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studyOral therapy for multiple myeloma: ixazomib arriving soon.Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.New orally active proteasome inhibitors in multiple myeloma.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.Oral ixazomib maintenance therapy in multiple myeloma.Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species.Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells.Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.Boronic acid-containing proteasome inhibitors: alert to potential pharmaceutical bioactivation
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Iksatsomibi
@fi
Ixazomib
@de
Ixazomib
@es
Ixazomib
@fr
Ixazomib
@vi
iksazomib
@nn
ixazomib
@en
ایکسازومیب
@fa
イキサゾミブ
@ja
type
label
Iksatsomibi
@fi
Ixazomib
@de
Ixazomib
@es
Ixazomib
@fr
Ixazomib
@vi
iksazomib
@nn
ixazomib
@en
ایکسازومیب
@fa
イキサゾミブ
@ja
altLabel
Ixazomib
@en
ixazomib
@nn
prefLabel
Iksatsomibi
@fi
Ixazomib
@de
Ixazomib
@es
Ixazomib
@fr
Ixazomib
@vi
iksazomib
@nn
ixazomib
@en
ایکسازومیب
@fa
イキサゾミブ
@ja
P486
P592
P6366
P638
P661
P662
P665
P683
P1579
P2017
B([C@H](CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O